| As of Tuesday's close, MDCX had 6 analyst targets pointing to a significant amount of upside potential.
In fact, with an average target of $23.50, MDCX could have over 900% potential upside from its closing valuation on November 11th.
MarketBeat reports further that Jason Kolbert of D. Boral Capital has given MDCX a $27 target representing a potential upside over 1,000% from Tuesday's close.
Additionally, the website shares Jason McCarthy of Maxim Group has provided a $20 target suggesting 700+% potential upside from Tuesday's close.
Could (Nasdaq: MDCX) be undervalued from current chart levels? -----
No. 4 MDCX Potential Catalyst - Medicus Pharma Expands Global Reach With UAE Sknjct-004 Phase 2 Clinical Study Advancement Milestone.
Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
Cleveland Clinic Abu Dhabi (CCAD) Is The Principal Investigator In This 36 Participant Study
PHILADELPHIA, PA / ACCESS Newswire / October 22, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce the enrollment of the first patient in United Arab Emirates (UAE) SKNJCT-004 phase 2 clinical study, to non-invasively treat BCC of the skin.
The study is expected to randomize thirty-six (36) patients in six sites in the UAE. In addition to Cleveland Clinic Abu Dhabi (CCAD), the study is also expected to commence patient recruitment in Sheikh Shakbout Medical City (SSMC), Burjeel Medical City (BMC), Rashid Hospital (RH), Clemenceau Medical Center (CMC) and American Hospital of Dubai (AHD).
Insights Research Organization and Solutions (IROS), a UAE-based contract research organization, is coordinating the clinical study for the Company. IROS is a M42 portfolio company.
"Treating our first BCC patient at Cleveland Clinic Abu Dhabi is an important milestone in expanding our clinical study beyond the shores of the United States," stated Dr. Raza Bokhari, Medicus's Executive Chairman & CEO. "Non melanoma Skin diseases, especially BCC is not just an American problem but a global challenge which we believe represents more than US$2Bn in potential market opp."
...
Read the full article here. -----
No. 5 MDCX Potential Catalyst - A Game-Changing Acquisition Is Completed!
Medicus Pharma Ltd. Completes Acquisition of Antev Limited
Antev is developing Teverelix, a next generation GnRH Antagonist, as a first in class market product for Acute Urinary Retention (AURr) and high CV risk Prostate Cancer collecting representing ~US$6Bn in potential market opp.
Patrick J. Mahaffy, a veteran pharma executive and the former Chairman of Antev, appointed to Medicus Board of Directors
Philadelphia, Pennsylvania--(Newsfile Corp. - September 2, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), ..., and Antev Limited ("Antev"), a UK-based clinical-stage drug development company, announced today that Medicus has acquired 98.6% of the issued and outstanding shares of Antev for aggregate consideration consisting of approximately US$2.97Mn in ca-sh and 1,603,164 common shares of Medicus, pursuant to the previously announced securities exchange agreement among Medicus, Antev and certain securityholders of Antev, dated as of June 29, 2025, as amended.
Antev is a clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as a first in market product for cardiovascular high-risk prostate cancer patients and patients with first acute urinary retention (AURr) episodes due to enlarged prostate.
Antev's former shareholders will be entitled to receive up to approximately US$65Mn in additional contingent consideration tied to potential future FDA Phase 2 and New Drug Application approvals.
Following the completion of the acquisition, Patrick J. Mahaffy, a veteran pharma executive and the former chairman of Antev, was unanimously appointed to Medicus's board of directors. Mr. Mahaffy is also the former CEO of both Clovis Oncology (NASDAQ: CLVS) and Pharmion Corporation (NASDAQ: PHRM).
...
"We are delighted to complete the acquisition of Antev, which not only adds strategic depth to our drug development pipeline but also strengthens our team, both at the board and management level," stated Dr. Raza Bokhari, Medicus's Executive Chairman & CEO. "We believe, Teverelix, a next generation GnRH antagonist, is well positioned to become a first in class product to prevent acute urinary retention relapse due to enlarged prostate, and to treat advanced prostate cancer in patients with high cardiovascular risk profile, collectively representing approximately US$6Bn in potential market opp."
...
Read the full article here. -----
(Nasdaq: MDCX) Recap - These 5 Potential Breakout Catalysts Lead The Way
No. 1 - A Low Float Could Create The Environment For Heightened Volatility.
No. 2 - MDCX Leads Innovative Collaboration Advancing Compassionate SKINJECT Access Globally.
No. 3 - An Average Of 6 Analyst Targets Suggest Major Upside Potential (Triple-Digit!).
No. 4 - Medicus Pharma Expands Global Reach With UAE Sknjct-004 Phase 2 Clinical Study Advancement Milestone.
No. 5 - A Game-Changing Acquisition Is Completed! -----
Medicus Pharma Ltd. (Nasdaq: MDCX) is on my radar as coverage is officially initiated.
Be on the lookout for updates coming shortly.
Sincerely, Kai Parker StockWireNews
(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)
*StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 11/11/2025 and ending on 11/12/2025 to publicly disseminate information about (MDCX:US) via digital communications. Under this agreement, SWN Media LLC has been paid seventeen thousand five hundred USD ("Funds"). To date, including under the previously described agreement, SWN Media LLC has been paid ninety thousand USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither SWN Media LLC, TD Media LLC and their member own shares of (MDCX:US).
Please see important disclosure information here: https://stockwirenews.com/disclosure/mdcx-vkc4o/#details | 
